Admission triglyceride-glucose index is predictor of long-term mortality and appropriate implantable cardiac defibrillator therapy in patients with heart failure

Biomark Med. 2023 May;17(10):487-496. doi: 10.2217/bmm-2023-0113. Epub 2023 Jul 31.

Abstract

Background: In this study, the main aim was to evaluate the relation of the triglyceride-glucose (TyG) index to long-term mortality and proper shock therapy in patients with an implantable cardiac defibrillator (ICD) implanted for heart failure with reduced ejection fraction. Methods: This retrospective study group consisted of 773 patients treated with ICD for heart failure with reduced ejection fraction. The long-term prognostic effect of the TyG index among tertiles was evaluated regarding mortality and appropriate ICD therapy. Results: In the adjusted model, the mortality rates were 14.0% (hazard ratio: 2.24; 95% CI: 1.42-6.88) in tertile 2 and 23.3% (hazard ratio: 3.88; 95% CI: 1.84-14.38) in tertile 3. Conclusion: The TyG index was found to be an independent predictive marker for both long-term mortality and appropriate ICD therapy.

Keywords: heart failure; implantable cardiac defibrillator; insulin resistance; mortality; triglyceride-glucose index.

MeSH terms

  • Defibrillators, Implantable*
  • Follow-Up Studies
  • Heart Failure* / therapy
  • Humans
  • Prognosis
  • Retrospective Studies
  • Risk Factors